Neurogene announces locations for Gene Therapy NGN-401 trial
On June 12 2023, Neurogene Inc. announced the locations and began enrolling for the first U.S. Phase 1/2 clinical trial of their investigational gene therapy, NGN-401. Enrollment at Texas Children's Hospital begins immediately, with enrollment at Children’s Hospital Colorado and Boston Children’s Hospital beginning soon – all three clinics part of IRSF’s Center of Excellence network.
